NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients

作者：Kuroda Junya^*; Kodama Ayumi; Chinen Yoshiaki; Shimura Yuji; Mizutani Shinsuke; Nagoshi Hisao; Kobayashi Tsutomu; Matsumoto Yosuke; Nakaya Yohei; Tamura Ayako; Kobayashi Yutaka; Naito Haruna; Taniwaki Masafumi

来源：Leukemia Research, 2014, 38(5): 619-624.

DOI：10.1016/j.leukres.2014.03.001

• JAK2
• CFU-GM
• Myelodysplastic syndrome
• NS-018
• STAT

JAK2/STAT signaling promotes survival and expansion of myelodysplastic syndrome (MDS) clones, but little is known about the potential of JAK2/STAT as a therapeutic target in MDS. We investigated the effect of NS-018, a novel antagonist for JAK2, on the colony-forming ability of bone marrow mononuclear cells (BMMNCs) from high-risk MDS patients. NS-018 decreased colony-forming unit-granulocyte/macrophage (CFU-GM) colony numbers from MDS-derived BMMNCs in a dose-dependent manner, and this effect was significantly more potent than against normal BMMNCs. In addition, NS-018 suppressed the phosphorylation of STAT3 in colony-forming cells from MDS patients. Collectively, NS-018 could be a new therapeutic option for high-risk MDS.

• 出版日期2014-5